← Leaderboards
Wendy K Rathmell
University Of Pennsylvania
$9,818,166
Attributed
$15,527,372
Total exposure
13
Grants
13
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.7M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$21,186,390 · 14
By mechanism
R01$6,973,453 · 4
P30$5,659,018 · 1
K12$4,864,771 · 1
T32$1,345,400 · 1
K24$869,915 · 1
K08$667,854 · 1
Top collaborators
- Ian J Davis7 shared
- Brian D Strahl7 shared
- Debra L Friedman6 shared
- Cheryl L Walker5 shared
- Ruhee Dere2 shared
- Frank M Mason1 shared
Most similar at University Of Pennsylvania
Same institution · by research overlap
- Andrei Thomas-Tikhonenko$8,144,872
- M. Celeste Simon$38,172,459
- Frank S Lee$12,269,170
- David C Fajgenbaum$7,024,320
- Dennis E. Discher$22,706,504
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsResearch PersonnelPathway InteractionsTumorMutationRenal Cell CarcinomaProgramsEnvironmentSignal TransductionRegulationPhenotypeMutantPropertyResponseKidney NeoplasmsDefectScientistGenesPatternRenal CarcinomaTranslational ResearchBaseGenomicsTumorigenesis
Grant awards (53)
Cancer Center Support Grant$5,659,018
P30 · FY2025 · CA · contact PI
Convergent Drivers of Tumor Evolution at the Mitotic Spindle$560,290
R01 · FY2023 · CA
Career Enhancement Program$95,582
P50 · FY2023 · CA · contact PI
Vanderbilt Clinical Oncology Research Career Development Award$795,679
K12 · FY2022 · CA · contact PI
Convergent Drivers of Tumor Evolution at the Mitotic Spindle$589,974
R01 · FY2022 · CA · contact PI
VIMORTP (Vanderbilt Integrated Molecular Oncology Research Training Program)$292,364
T32 · FY2022 · CA · contact PI
Career Enhancement Program$95,581
P50 · FY2022 · CA · contact PI
VIMORTP (Vanderbilt Integrated Molecular Oncology Research Training Program)$187,628
T32 · FY2021 · CA · contact PI
Career Enhancement Program$83,300
P50 · FY2021 · CA · contact PI
Vanderbilt Clinical Oncology Research Career Development Award$934,031
K12 · FY2020 · CA · contact PI
Methyltransferase Contributions to Genomic Stability and Cancer$432,911
R01 · FY2020 · CA · contact PI
VIMORTP (Vanderbilt Integrated Molecular Oncology Research Training Program)$296,949
T32 · FY2020 · CA · contact PI
Career Enhancement Program$88,865
P50 · FY2020 · CA · contact PI
Vanderbilt Clinical Oncology Research Career Development Award$919,030
K12 · FY2019 · CA · contact PI
Chromatin maintenance in cancer progression$446,600
R01 · FY2019 · CA · contact PI
Methyltransferase Contributions to Genomic Stability and Cancer$419,923
R01 · FY2019 · CA · contact PI
VIMORTP (Vanderbilt Integrated Molecular Oncology Research Training Program)$326,709
T32 · FY2019 · CA · contact PI
Career Enhancement Program$96,827
P50 · FY2019 · CA · contact PI
Vanderbilt Clinical Oncology Research Career Development Award$961,183
K12 · FY2018 · CA · contact PI
Chromatin maintenance in cancer progression$459,749
R01 · FY2018 · CA · contact PI
Methyltransferase Contributions to Genomic Stability and Cancer$432,911
R01 · FY2018 · CA · contact PI
VIMORTP (Vanderbilt Integrated Molecular Oncology Research Training Program)$241,750
T32 · FY2018 · CA · contact PI
Vanderbilt Clinical Oncology Research Career Development Award$800,773
K12 · FY2017 · CA · contact PI
Methyltransferase Contributions to Genomic Stability and Cancer$426,354
R01 · FY2017 · CA · contact PI
Chromatin maintenance in cancer progression$362,158
R01 · FY2017 · CA · contact PI
Enhancing Translational Science via Prospective Investigation$162,880
K24 · FY2017 · CA · contact PI
Chromatin maintenance in cancer progression$459,687
R01 · FY2016 · CA · contact PI
Vanderbilt Clinical Oncology Research Career Development Award$454,075
K12 · FY2016 · CA · contact PI
Methyltransferase Contributions to Genomic Stability and Cancer$440,854
R01 · FY2016 · CA · contact PI
Enhancing Translational Science via Prospective Investigation$162,880
K24 · FY2016 · CA · contact PI
Exploiting Notch inhibition as a mechanism to overcome resistance in ccRCC$149,317
R21 · FY2016 · CA · contact PI
Chromatin maintenance in cancer progression$97,197
R01 · FY2016 · CA · contact PI
Chromatin maintenance in cancer progression$254,979
R01 · FY2015 · CA · contact PI
Chromatin maintenance in cancer progression$217,376
R01 · FY2015 · CA · contact PI
Exploiting Notch inhibition as a mechanism to overcome resistance in ccRCC$196,011
R21 · FY2015 · CA · contact PI
Enhancing Translational Science via Prospective Investigation$95,013
K24 · FY2015 · CA · contact PI
Enhancing Translational Science via Prospective Investigation$67,867
K24 · FY2015 · CA · contact PI
Enhancing Translational Science via Prospective Investigation$18,505
K24 · FY2015 · CA · contact PI
Enhancing Translational Science via Prospective Investigation$181,385
K24 · FY2014 · CA · contact PI
Enhancing Translational Science via Prospective Investigation$181,385
K24 · FY2013 · CA · contact PI
Genetic Events in the Development of Renal Cell Carcinoma$267,870
R01 · FY2011 · CA · contact PI
Genetic Events in the Development of Renal Cell Carcinoma$276,155
R01 · FY2010 · CA · contact PI
Genetic Events in the Development of Renal Cell Carcinoma$276,155
R01 · FY2009 · CA · contact PI
Genetic Events in the Development of Renal Cell Carcinoma$276,155
R01 · FY2008 · CA · contact PI
Genetic Events in the Development of Renal Cell Carcinoma$276,155
R01 · FY2007 · CA · contact PI
Functional and Tissue Specific Effects of VHL Mutations$132,498
K08 · FY2007 · CA · contact PI
Functional and Tissue Specific Effects of VHL Mutations$132,498
K08 · FY2006 · CA · contact PI
CALGB 90206: INTERFERON ALFA-2B OR 2B PLUS BEVACIZUMAB IN RENAL CARCINOMA$248
M01 · FY2006 · RR · contact PI
DENDRITIC CELL VACCINE (MB-002) TO PATIENTS WITH METASTATIC RENAL CELL CARCINOMA$248
M01 · FY2006 · RR · contact PI
Functional and Tissue Specific Effects of VHL Mutations$132,498
K08 · FY2005 · CA
Functional and Tissue Specific Effects of VHL Mutations$132,498
K08 · FY2004 · CA
Functional and Tissue Specific Effects of VHL Mutations$115,812
K08 · FY2003 · CA
Functional and Tissue Specific Effects of VHL Mutations$22,050
K08 · FY2003 · CA